Long-term Safety and Efficacy of Dupilumab in Patients With Uncontrolled, Moderate-to-Severe Asthma Recruited From Korean Centers: A Subgroup Analysis of the Phase 3 LIBERTY ASTHMA TRAVERSE Trial

RECOMMENDED

COPD

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS, COURSE study investigators

doi: 10.1016/S2213-2600(24)00324-2

RECOMMENDED

AsthmaFurther Publications

Rademikibart Treatment for Moderate-to-Severe, Uncontrolled Asthma: A Phase 2B Randomized Trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Am J Respir Crit Care Med

Kerwin E, Yang T, Su N, Guo J, Adivikolanu R, Longphre M, Wang J, Yun J, Pan W, Wei Z, Collazo R

doi: 10.1164/rccm.202409-1708OC

Asthma

Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)

Allergy Asthma Immunol Res

Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH

doi: 10.4168/aair.2025.17.3.384

RECOMMENDED

Further Publications

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Am J Respir Crit Care Med

Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M, VX17-445-105 Study Group

doi: 10.1164/rccm.202411-2231OC

COMMENTED

Bronchi

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

Lancet Respir Med

Haworth CS, Shteinberg M, Winthrop K, Barker A, Blasi F, Dimakou K, Morgan LC, O'Donnell AE, Ringshausen FC, Sibila O, Thomson RM, Carroll KJ, Pontenani F, Castellani P, Chalmers JD, PROMIS trial investigators

doi: 10.1016/S2213-2600(24)00225-X

ERS 2024

Asthma

TRAVERSE: Dupilumab reduces severe asthma exacerbation rates and improves lung function regardless of increases in blood eosinophil counts

COMMENTED

COPD

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB

doi: 10.1016/S2213-2600(24)00409-0

Asthma

Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry

J Asthma Allergy

Le TT, Price DB, Erhard C, Cook B, Quinton A, Katial R, Christoff GC, Perez-de-Llano L, Altraja A, Bergeron C, Bourdin A, Koh MS, Lehtimäki L, Mahboub B, Papadopoulos NG, Pfeffer P, Rhee CK, Carter V, Martin N, Tran TN, EVEREST Study Working Group

doi: 10.2147/JAA.S468068

COMMENTED

Asthma

Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Castro M, Papi A, Porsbjerg C, Lugogo NL, Brightling CE, González-Barcala FJ, Bourdin A, Ostrovskyy M, Staevska M, Chou PC, Duca L, Pereira AM, Fogarty C, Nadama R, Zhang M, Rodrigues A, Soler X, Sacks HJ, Deniz Y, Rowe PJ, de Prado Gómez L, Jacob-Nara JA

doi: 10.1016/S2213-2600(24)00362-X

Related content

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial

Rademikibart Treatment for Moderate-to-Severe, Uncontrolled Asthma: A Phase 2B Randomized Trial

Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

TRAVERSE: Dupilumab reduces severe asthma exacerbation rates and improves lung function regardless of increases in blood eosinophil counts

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry

Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial